VIA Pharmaceuticals (VIAP) jumped in pre-market trading, after announcing worldwide licensing agreements with Roche for two sets of compounds.
The stock was up 17 cents just before 8:55 am ET, soaring to 30 cents. If pre-market gains hold, the stock will open at its highest level in two weeks.
Tuesday, VIA Pharmaceuticals said it signed exclusive, worldwide licensing agreements with Roche for two sets of compounds. The first was for Roche's thyroid hormone receptor beta agonist, a clinically ready candidate for the control of cholesterol, triglyceride levels and potential in insulin sensitization/diabetes. The second was for multiple compounds from Roche's preclinical diacylglycerol acyl transferase 1 metabolic disorders program.
Under the terms of the agreements, VIA will assume control of all development and commercialization of the compounds, and will own exclusive worldwide rights for all potential indications. The agreements provide for milestone payments for development and royalties upon commercialization.
VIA Pharmaceuticals Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.